Xiamen University

Xiamen Innovax Biotech Co., Ltd.

Xiamen Innodx Biotech Co., Ltd.

Feihai Xu

Shengxiang Ge

Jun Zhang

Ningshao Xia

Liuwei Song

Zuxing Weng

Quan Yuan

Jin Wang

Tingdong Li

Shiyin Zhang

Haijun Lin

Jinjie Li

Wenbin Zhou

Qingshun Guo

Shunhua Wen

Xudong Sun

A kit for quantitatively detecting HBsAg and a method for quantitatively detecting an HBsAg content in a sample containing HBsAg. The kit comprises a first antibody specifically binding to HBsAg and a reagent composition. The reagent composition comprises tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and urea.

Kit and method for quantitative detection of HBsAg

Disclosed are a reaction tube for nucleic acid amplification capable of controlling a liquid circulation path, a reaction apparatus for nucleic acid amplification comprising the reaction tube, and a method for amplifying nucleic acid comprising a step of using the reaction tube. Also disclosed are a kit comprising the reaction tube, and use of the reaction tube in preparation of a kit.

Reaction tube for nucleic acid amplification capable of controlling liquid circulation path

The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analog anti-HBV drug), and thus guide the patients to reasonably choose drugs.

Anti-HBc quantitative detection method and uses thereof in monitoring and controlling disease progression of chronic hepatitis B patient and in predicting therapeutic effect

The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.

Method for in-vitro preparation of double-layered virus-like particles of rotavirus

Growing community of inventors

Xiamen, China

Feihai Xu